Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2026)
Entrada Therapeutics' EBIT Margin came in at -5007.02% for Q2 2026, down 2604.50 percentage points from -2402.51% a year earlier and down 172.39 percentage points from the prior quarter.
Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Entrada Therapeutics reported EBIT Margin of -3767.07%, down 3646.07 percentage points year-over-year; for FY2025, it was -621.13%, down 643.44 percentage points from FY2024.
- Going back by year, EBIT Margin was 22.30% in FY2024 (+24.75 pp) and -2.45% in FY2023.
- The Q2 2026 figure represents the lowest quarterly EBIT Margin in data going back to Q1 2023.
- Year-over-year, EBIT Margin has declined for eight consecutive quarters, with an average year-over-year change of -2017.75 percentage points over the last eight quarters.
- The fastest year-over-year change in EBIT Margin over five years came in Q2 2024 (a gain of 146.12 percentage points), and the weakest in Q1 2026 (a drop of 4728.64 percentage points).
- Business Quant data shows TRDA's EBIT Margin at -4834.63% (Q1 2026), -3249.27% (Q4 2025) and -2915.18% (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 37.40% |
| 10 | Entrada Therapeutics | 243.74 Mn | 243.74 Mn | - | -5,007.02% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,007.02% |
| Mar 31, 2026 | -4,834.63% |
| Dec 31, 2025 | -3,249.27% |
| Sep 30, 2025 | -2,915.18% |
| Jun 30, 2025 | -2,402.51% |
| Mar 31, 2025 | -105.99% |
| Dec 31, 2024 | -15.69% |
| Sep 30, 2024 | -110.67% |
| Jun 30, 2024 | 56.42% |
| Mar 31, 2024 | 35.71% |
| Dec 31, 2023 | 11.72% |
| Sep 30, 2023 | 32.04% |
| Jun 30, 2023 | -89.70% |
| Mar 31, 2023 | -22.88% |
Entrada Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();